GSK1349572

DRUG19 trials

Sponsors

GlaxoSmithKline, ViiV Healthcare

Conditions

HIV InfectionsHealthy SubjectsHealthy VolunteerHepatic ImpairmentInfection, Human Immunodeficiency VirusInfection, Human Immunodeficiency Virus IInfections, Human Immunodeficiency Virus and HerpesviridaeInfections, Human Immunodeficiency Virus and Tuberculosis

Phase 1

GSK1349572 First Time in Human Study

CompletedNCT00555035

GlaxoSmithKlineHealthy Subjects

Start: 2007-11-30End: 2008-02-29Updated: 2010-10-15

GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study

CompletedNCT00631592

ViiV HealthcareHealthy Subjects

Start: 2008-02-29End: 2008-06-30Updated: 2017-02-03

GSK1349572 Drug Interaction Study With Protease Inhibitors

CompletedNCT00774735

GlaxoSmithKlineHealthy Subjects, Infection, Human Immunodeficiency Virus

Start: 2008-10-31End: 2008-12-31Updated: 2010-09-13

GSK1349572 Drug Interaction Study With Etravirine

CompletedNCT00774111

GlaxoSmithKlineHealthy Subjects

Start: 2008-10-31End: 2008-12-31Updated: 2009-06-05

A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572

CompletedNCT00858455

GlaxoSmithKlineHealthy Volunteer

Start: 2009-01-31End: 2009-03-31Updated: 2009-06-05

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

CompletedNCT00867152

ViiV HealthcareHealthy Volunteer

Start: 2009-04-30End: 2009-05-31Updated: 2012-02-22

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

CompletedNCT00883935

GlaxoSmithKlineHealthy Volunteer

Start: 2009-04-30End: 2009-06-30Updated: 2009-06-22

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study

CompletedNCT00942136

GlaxoSmithKlineHealthy Volunteer

Start: 2009-07-31End: 2009-09-30Updated: 2009-10-09

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

CompletedNCT01068925

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2010-02-15End: 2010-04-05Updated: 2019-06-24

GSK1349572 Drug Interaction Study With Efavirenz

CompletedNCT01098526

ViiV HealthcareInfections, Human Immunodeficiency Virus and Herpesviridae

Start: 2010-03-16End: 2010-05-26Updated: 2017-09-25

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

CompletedNCT01209065

ViiV HealthcareInfections, Human Immunodeficiency Virus and Herpesviridae

Start: 2010-09-30End: 2010-11-30Updated: 2017-01-19

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

CompletedNCT01214993

ViiV HealthcareInfections, Human Immunodeficiency Virus and Tuberculosis

Start: 2010-10-31End: 2010-11-30Updated: 2012-06-11

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

CompletedNCT01231542

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2011-05-31End: 2011-12-31Updated: 2017-06-08

GSK1349572 Hepatic Impairment Study

CompletedNCT01231529

ViiV HealthcareHealthy Subjects, Hepatic Impairment, HIV Infections +1

Start: 2010-11-19End: 2011-06-04Updated: 2019-07-31

A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.

WithdrawnNCT01283100

ViiV HealthcareInfection, Human Immunodeficiency Virus I

Start: 2011-03-31End: 2011-06-30Updated: 2014-12-24

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects

CompletedNCT01332565

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2011-04-30End: 2011-06-30Updated: 2011-06-27

Phase 2

Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

CompletedNCT00708110

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2008-06-30End: 2008-08-31Updated: 2013-12-05

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

CompletedNCT00951015

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2009-07-30End: 2016-12-22Updated: 2018-01-16

Phase 3

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

CompletedNCT01231516

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2010-10-26End: 2021-02-02Updated: 2022-03-15

Related Papers

Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV

The Journal of Infectious Diseases2025-09-24

Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin.

2022-05-2316 citations

Effect of Fosamprenavir-Ritonavir on the Pharmacokinetics of Dolutegravir in Healthy Subjects

Antimicrobial Agents and Chemotherapy2014-08-2613 citations

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

2013-07-03425 citations

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

2011-10-20231 citations